After stroke, physiotherapy can promote brain reorganization and motor recovery. Combining muscle strength and functional training (functional strength training, FST) may be beneficial. The aim of the authors was to compare FST with conventional physiotherapy (CPT) while controlling for the potential confounder of therapy intensity in a multicenter, randomized controlled observer-blind trial. The mean age of the participants was 68.3 (standard deviation [SD] = 12.03) years at a mean of 34 (SD = 20) days after stroke, with mean peak paretic knee extension torque (torque) of 22 (SD = 25) Nm. The estimated sample size was 102 to detect a between-group difference of 0.2 m/s in walking speed. After baseline measures, participants were allocated randomly to CPT or CPT + CPT or CPT + FST for 6 weeks. Additional experimental therapy was provided for up to 1 hour a day, 4 times each week. Outcomes were measured 6 weeks after baseline and at follow-up 12 weeks thereafter. Measures included walking speed, knee extensor torque, and functional mobility (Rivermead). At outcome, both extraintensity groups showed greater increases in walking speed than the CPT group, but this reached significance only for the CPT + CPT group (P = .031). The CPT + CPT group also had a greater number of participants who walked at 0.8 m/s or above. No significant differences were observed for torque about the knee or for the Rivermead score. At follow-up, no significant differences were observed. These phase I results justify a subsequent trial of CPT + CPT versus CPT + FST.
Introduction
Physical therapy can promote brain reorganization and motor recovery after stroke. 1 Yet which interventions are most beneficial for which stroke survivors remains unknown. 2 Retraining of functional activity may be beneficial, 3 and resistive exercise to increase muscle strength is considered positively in guidelines 4 although it remains underevaluated. Systematic reviews of resistive exercise have concluded that there is only preliminary evidence for increased muscle strength to be accompanied by improved functional ability. 5 However, increased muscle strength might be related to improvements in functional ability if resistive exercise is provided during functional tasks. 6 Such functional strength training (FST) may be more effective than no therapy, 7 and both functional training and strength training delivered in addition to standard care for the upper limb may be more effective than standard care alone. 8 Furthermore, preliminary evidence suggests that FST given in addition to conventional physiotherapy (FST + CPT) might have more effect on upper-limb motor function than either extraintensity CPT (CPT + CPT) or CPT alone. 9 The hypothesis is therefore that FST + CPT for the paretic lower limb produces greater improvements in motor recovery than either CPT + CPT or CPT alone. In preparation for a subsequent phase II trial this phase I trial investigated the following:
1. whether it is feasible to deliver the planned amount of additional physical therapy;
2. whether there is sufficient efficacy for FST + CPT and CPT + CPT to justify a subsequent 3-group Phase II randomized clinical trial to evaluate clinical efficacy; and 3. what are the likely recruitment rate, attrition rate and sample size of a subsequent randomized clinical trial.
Methods
An observer-blind, randomized controlled phase I trial was carried out (Figure 1 ). Participants provided written informed consent and then completed baseline measures. Intervention began on the following day for 6 weeks. Participants repeated the measurement battery on completion of the intervention phase (outcome) and 12 weeks later (follow-up). Every effort was made to measure participants at outcome and follow-up even if they had withdrawn from therapy (intention-to-treat principle). Ethical approval was obtained from the local research ethics committees covering the clinical centers. The clinical trial registration number is NCT00322192.
An independent statistician produced a pretrial computergenerated randomized group allocation order in blocks of 9 per trial center. Allocation was stratified by baseline scores for unilateral visual spatial neglect (Star Cancellation Test, 50-54 no spatial neglect and 0-49 unilateral spatial neglect present). Allocation was concealed in sequentially numbered sealed opaque envelopes held by an independent administrator. Envelopes were opened in response to a telephone request from the research physiotherapist (blinded to measures) after the assessor (blinded to group allocation) had completed baseline measures.
Participants
There were 3 initial clinical centers. A fourth center was added in the trial's last year to ensure that the estimated sample size was achieved. Participants possessed the following characteristics:
· they were inpatients older than 18 years, between 1 and 13 weeks after anterior circulatory stroke (hemorrhage or infarction); · some voluntary muscle contraction in the paretic lower limb (a score of at least 28/100 on the lower limb section of the motricity index),with potential for clinically important improvement was present; · they were able to follow a 1-stage command; · they were independently mobile, with or without aids, prior to the index stroke; and · there was no orthopedic surgery and no trauma affecting the lower limb in the last 8 weeks, and there was no previous history of neurological disease other than stroke.
The study criteria were designed to reflect the aspects of clinical presentation that physiotherapists consider when making clinical judgments about which interventions to provide for individuals after stroke.
Sample Size
There were no directly relevant data available to inform a power calculation when this early phase trial was planned. We assumed a standard deviation (SD) of increase in walking speed of 0.3 m/s in the control and experimental groups based on data of a comparison of walking interventions early after stroke. 10 The sample size of 36 per group provides 80% power at 5% twosided significance to detect a mean relative difference between groups of 0.2 m/s in walking speed (0.1 m/s is a clinical effect).
Interventions
All participants received routine CPT from their clinical physiotherapists using a treatment schedule. 11 The content and duration of each session was recorded. Routine CPT included soft tissue mobilization, facilitation of muscle activity, facilitation of coordinated multijoint movement, tactile and proprioceptive input, resistive exercise, and functional retraining. 11 All additional physical therapy, both CPT and FST, was delivered using standardized treatment schedules for up to 1 hour, 4 days a week for 6 weeks (24 hours) by research physio-therapists who were independent of the clinical team. Four research physiotherapists provided the experimental interventions over the course of the trial but for any clinical center at any time point the same research physiotherapist provided both forms of experimental intervention. To ensure adherence to experimental treatment schedules, the research physiotherapists were supervised throughout the trial. The clinical team was given no information about participants' group allocation and was not present when the additional intervention was provided. If participants were discharged from inpatient care before the end of the 6-week intervention phase then a prepaid return taxi journey was arranged to enable attendance at therapy sessions.
The control condition was CPT. 11 Participants allocated to this condition did not receive any additional therapy. Experimental condition 1 was CPT 11 plus CPT (CPT + CPT). To provide clear differentiation between the 2 CPT conditions, the experimental CPT focused on those interventions in the treatment schedule 11 that emphasized control/quality of movement and gave prominence to sensory stimulation and preparation of joint and muscle alignment prior to activating muscle or a functional task. Additional CPT was therefore strongly therapist hands-on, with provision of passive movements, active assisted exercise, and/or hands-on intervention to facilitate muscle activity or functional ability. Some active exercise and repetitive practice of functional tasks was included but without systematic progression in resistance or repetition. The key differences between experimental CPT and experimental FST are outlined in Appendix 1.
Experimental condition 2 was FST + CPT. Delivery of FST directed participants' attention to the exercise/activity being performed, appropriate verbal feedback on performance, and repetition (therapist hands-off). Content of FST focused on repetitive, progressive resistive exercise during goal-directed functional activity. The emphasis was on producing appropriate muscle force for the functional activity being practiced. Treatment progressed systematically using repetition and increase in resistance by, for example, changing the limb's relationship to gravity, increasing the range of movement or distance over which bodyweight was transported, and changing the weight of external objects used to provide resistance. Treatment activities progressed systematically from light to heavy loads and from few to many repetitions. Participants performed repetitive exercise of functional tasks such as sit-to-stand-to-sit, stair climbing/ step ups, inside and outside walking, transfer training, bed mobility, and treadmill training with and without the use of a bodyweight support system. Further information is provided in Appendix 2.
Primary Outcome Measure
Walking speed (meters per second) was obtained as participants walked in a straight line on a flat floor independently for 10 m. The VICON movement analysis system was used for participants in clinical centers within a 30-minute taxi journey of the gait laboratory and the 10-m walking test was used with the remainder. This difference arose because a fourth clinical center was included in the trial to ensure that the estimated sample size was achieved. No individual participant was assessed using both forms of measurement, and change scores were used in the statistical analysis to compare groups at outcome and at follow-up.
Secondary Outcome Measures
The secondary outcome measures were as follows:
· ability to walk at 0.8 m/s or more-the walking speed that indicates community mobility 12 ; · torque around the paretic knee during concentric isokinetic extension followed immediately by flexion using the CYBEX NORM isokinetic dynamometer in "passive mode" at 60 degrees per second 13 ; the mean of 3 repetitions, separated by 60 seconds, was used for analysis; · the modified Rivermead mobility index 14 ; · temporal-spatial gait parameters-hemiplegic gait is characterized by asymmetry of footsteps 15 ; temporal-spatial gait parameters measured in this trial were symmetry of step length and step time, and symmetry was calculated as the percentage value from 100% (representing total symmetry) using the formula (paretic side/nonparetic side) × 100; and · the health status and health-related quality of life as measured by the EuroQuol. 16 Analysis Analysis of covariance was performed adjusting for baseline values of the outcome measure and the potential influence of unilateral visual spatial neglect (stratification variable). To allow for the nonlinearity of the relationship between baseline and outcome walking speed, baseline walking speed was divided into 4 categories: (1) zero walking speed; (2) between 0.01 m/s to 0.3 m/s; (3) between 0.31 m/s and 0.60 m/s; and (4) greater than 0.61 m/s. The nonparametric bootstrap with 50 000 iterations was used because of the nonnormality of the residuals from the model. For those who were unable to walk, we imputed a value of 0 for both walking speed and step length but treated step time as missing data. Because of the distance to one of the centers, it was not possible to measure walking speed using the same instruments for the participants from this center. Because the analysis is adjusted for the baseline values and the relationship between follow-up, outcome, and baseline measurements is expected to be the same regardless of the instrument used, the analysis should be unbiased by this effect.
A power calculation to estimate sample size for subsequent phase II and III trials was undertaken. This was based on comparing change from baseline in walking speed between 2 treatment arms using a 2-sample t test, with a clinically important difference of 0.1 m/s, and the SD of change from baseline to outcome found in the CPT group with 90% power and 5% significance.
Results
In summary, 1116 individuals were screened for inclusion in this trial, of whom 178 (16 %) were eligible, but 69 (38 %) of these refused informed consent. Consequently, 109 (10%) of those screened were randomized as follows: 38 to CPT, 35 to CPT + CPT, and 36 to FST + CPT. At outcome, 10 (9%) participants had withdrawn. At follow-up, a further 18 participants had withdrawn (26%; Figure 1 ).
All measures were balanced at baseline with the exception of hemiplegic side and number able to walk at 0.8 m/s or more (Table 1) . Baseline walking speed did not differ between those participants available at outcome and those who dropped out (P = .6147) or at follow-up (P = .2057). None of the baseline measures was predictive of dropout, using a logistic regression model.
Over the 6-week intervention period, the mean duration of CPT provided by the clinical physiotherapists for all participants was 8.5 accumulated hours ( Table 2 ). The mean duration of additional therapy received by the 2 experimental groups was essentially equal, being 15.7 accumulated hours of CPT for the CPT + CPT group and 14.8 accumulated hours of FST for the FST + CPT group.
Walking speed increased for all groups from baseline (Table 1) to outcome to follow-up ( Table 3 ). The experimental groups improved more than the CPT group (control) at both outcome and follow-up, and this was statistically significant at outcome for the CPT + CPT group (P = .031).
More participants in the experimental groups achieved a walking speed of 0.8 m/s at outcome and follow-up than the CPT group. This was significant at outcome for the CPT + CPT group (P = .038). All groups showed improved peak torque about the paretic knee at outcome and follow-up, but this was most evident in the 2 experimental groups ( Table 4 ). The advantage of extra therapy was statistically significant for the CPT + CPT group for knee flexion peak torque at outcome (P = .016).
At outcome, the CPT + CPT group was more symmetrical for both step time and step length than either of the other groups. At follow-up, the CPT + CPT group was more symmetrical for step time and the CPT group for step length. None of these differences reached statistical significance ( Table 3) .
All groups showed improvements from baseline to follow-up for the modified Rivermead index and EuroQuol measures, but no statistically significant differences were observed (Tables 4 and 5 ).
The SD for change from baseline in walking speed in the CPT group was 0.25 at outcome and 0.33 at follow-up. Thus, for a future trial to have 90% power to detect the clinically important difference of 0.1 m/s, it would require 129 participants per group (248 in total) at outcome and 224 at follow-up; allowing for a 26% attrition rate would increase this to 303 per group.
Discussion
These phase I results indicate advantages for extra intensity physical therapy, both CPT and FST, which reached statistical significance at outcome for walking speed, ability to walk at 0.8 m/s or more, and torque about the knee during flexion for the group receiving extra CPT. This trial has also provided data to inform subsequent evaluation to determine the clinical efficacy of CPT + CPT and FST + CPT. Subsequent trials should be designed considering the 16% eligibility rate, 10% recruitment rate, and the attrition rates of 9% at outcome and 26% at follow-up. The 3-group trial design was found to be feasible early after stroke, and the sample size for a subsequent clinical efficacy trial has been estimated as 330 per group (660 in total). It is interesting that the group receiving additional physical therapy in the form of CPT showed greater improvement than the group that received it in the form of FST. This finding contrasts with the findings of our phase I trial comparing the same interventions for the upper limb in which a trend for a greater improvement was found for those participants receiving FST + CPT. 9 The findings reported here also contrast with the systematic review findings of advantages of training functional activity in earlier trials 5 and the finding that the Bobath approach, on which CPT is based, is not superior to other approaches. 17, 18 Four possible reasons for the differences are discussed below.
First, most comparator trials did not include strength training and used different control interventions. For example, immobilization in a splint versus task-specific training 19 contrasts with CPT versus FST in the present trial. It may be expected therefore that results might differ.
Second, there is a possibility of a type I error. The sample size calculation using data from the present trial estimates that 660 participants would be needed to provide definitive evidence of effectiveness. However, the focus of the present trial was to determine if there was sufficient evidence of efficacy to justify proceeding to a larger effectiveness trial. This is now justified by these results.
Third, the CPT evaluated in the present trial included some functional training. 11 This was recognized as a potential confounding factor, and therefore, the extra experimental CPT emphasized sensorimotor interventions to enhance control and quality of movement. Any active exercise and functional task practice provided as part of additional CPT for the CPT + CPT group was given without systematic progression in repetition or resistance to movement. The emphasis was on provision of sensory stimulation and preparation of joint and muscle alignment prior to activating muscle or a functional task. It remains possible, however, that the functional activity included in routine CPT eroded the planned difference with experimental FST. However, as routine CPT was provided to all participants, the randomization procedure should have controlled for this potential confounding factor.
Fourth, it is possible that an insufficient dose of FST was delivered. Only approximately 60% of the planned 24 hours of additional physical therapy was delivered. However, the amounts of extra therapy provided for the upper limb for which benefit was suggested 9 were less than those for the lower limb in the present trial: 10.5 (SD = 4.9) accumulated hours for CPT compared with 15.7 (SD = 4.7) accumulated hours, and 12.5 (SD = 4.2) accumulated hours for FST compared with 14.8 (SD = 4.3) accumulated hours. This raises the possibility that the lower-limb CPT in the United Kingdom is sufficient in terms of amount. This appears unlikely as better outcomes in non-UK centers have been associated with provision of higher intensity therapy. 20 Another possibility is that outside of physical therapy sessions, a higher level of activity is provided for the lower limb than for the upper limb in routine clinical personal care activities such as dressing and toileting. Consequently, the routine lowerlimb activity could have added to the benefit of routine CPT, and the extra FST was insufficient to provide further benefit. Conclusions cannot be made from the findings of this early phase trial. Further investigation is required of factors influencing the most appropriate dose of CPT + CPT and FST + CPT and adherence to these. Although a systematic review has indicated the need for at least an additional 16 hours of therapy, 21 the primary trials are confounded by comparisons of both different types and intensities of therapy. Restricting comparisons to different intensities of the same therapies in a systematic review yielded only 5 primary trials. 22 Benefits were found for lower-limb recovery. All but one of these, however, emerged from an RCT that compared functional training with the application of an immobilizing splint. 19 This is insufficient evidence on which to continue to base the most appropriate dose of experimental therapies for subsequent trials. Specific dose finding studies are required.
Further research also needs to consider the potential influence of adherence to dose. Nonadherence was considered unlikely during the planning stages of the present trial because stroke survivors spend much of the day alone and unengaged in therapeutic activity 20 and report dissatisfaction with the amount of therapy received. 23 Consequently, we anticipated that delivery of an extra 24 hours over 6 weeks might only be difficult if participants were discharged from inpatient care. To minimize the possibility of nonadherence, we arranged prepaid taxis for those discharged from inpatient care, but this might have been insufficient to ensure adherence to the planned dose. Maximizing delivery of the planned dose of CPT + CPT and FST + CPT in subsequent trials therefore requires a better understanding of reasons for nonadherence. This will inform strategies for delivering higher doses in subsequent trials. It is not possible to identify these from the present trial as it was not designed to collect the required data prospectively and systematically.
Conclusion
This phase I trial has provided sufficient evidence to justify and inform the design of subsequent trials of CPT + CPT and FST + CPT. Attention now needs to be given to identification of the most appropriate dose of both experimental CPT and FST and how adherence can be increased. Combining data from these further investigations will inform the dose and delivery of CPT + CPT and FST + CPT for the determination of definitive clinical effectiveness in a subsequent phase II trial. 
Appendix 1. Outline of Key Differences Between

Progression of therapy Repetition
Five or fewer repetitions of the same specific task One or more sets of 10 repetitions of the same specific task, with up to 5 sets of 10 repetitions
Resistance progression
No systematic progression in treatment activities Systematic progression in treatment activities from increasing the amount of an individual's bodyweight that they need to move and also the distance over which they need to move it. A task is begun with a resistance that allows a 5-repetition maximum load throughout the whole available range of the muscle length. Progressed when the patient can achieve 50 repetitions (5 sets of 10) against the initial load. For example, practicing standing up initially from a starting hip flexion angle of 40° (perch sitting) and progressing to a starting hip flexion angle of 120°. Another example is gradually reducing the amount of bodyweight support during treadmill walking from an initial level of 60% and increasing the distance walked
Appendix 2. Examples of Activities Used in the Functional Strength Training Intervention
1. Training of concentric and eccentric muscle activity during sit-stand and stand-to-sit without using upper limbs to aid activity. Each participant started on an adjustable plinth at a height from which approximately 5 repetitions of the entire cycle (stand up and sit down) could be completed without resting between cycles. Once the participant could achieve approximately 5 sets of 10 repetitions, the height of the plinth was lowered. If the participant found one aspect of the cycle more difficult (either standing up or sitting down), the height of the plinth was varied within the session, or upper limbs were used to assist the more difficult movement. Progression continued until the participant was able to complete 10 repetitions of the entire cycle from a starting point of 120° hip flexion.
Training concentric and eccentric muscle activity during
walking on a treadmill on a level, inclined, and declined surface was given with and without partial bodyweight support (PBWS). PBWS was provided to the point where each participant could bear weight on the paretic leg during the single stance phase of gait without knee collapse (maximum 60% PBWS). PBWS was progressively decreased as participants improved. Initially they walked at a rate at which they felt most comfortable, and the velocity of the treadmill was correspondingly set. If the participant was unable to actively step their paretic leg, assistance in placing the foot was given by the treating therapist through the use of foot and ankle orthoses. Care was taken not to use "facilitation" techniques during placing the foot. When the participant was confident walking on the treadmill, sessions were varied to work either on endurance speed of walking or walking uphill and downhill. Interval training was used to progress speed, for example, fast walking for a set time with a slower pace recovery. Endurance sessions involved steady pace over a set distance progressing to 1000 meters. Once this was achieved, pace changes and hill climbs were added to the endurance session. The maximum time participants spent on the treadmill was 40 minutes during 1 session. For each session, the PBWS, time, velocity, incline/decline, and distance walked was recorded. 3. Training concentric and eccentric muscle activity during ascending and descending stairs or step: the initial height of the step was determined by assessing the participant's ability to place the paretic foot on and off 1 step approximately 5 times. The exercise was then progressed through placing alternate feet on and off the step (1 cycle) until 5 sets of 10 cycles were completed, and then the height of the step was raised. The same process was used for descending a step. The exercise was further progressed by increasing the height of the step and reducing the use of upper limbs for support. Progression continued until a participant could complete 5 sets of 10 repetitions of ascending and descending a flight of stairs without using arms for support.
